Literature DB >> 12710128

The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis.

Cynthia M Magro1, James Allen, Amy Pope-Harman, W James Waldman, Patrick Moh, Susan Rothrauff, Patrick Ross.   

Abstract

Interstitial lung disease compatible with idiopathic pulmonary fibrosis (IPF) developed in 19 previously healthy patients. Although interstitial and/or honeycomb parenchymal fibrosis was present in all, there were patchy areas of paucicellular septal capillary injury along with corroborative direct immunofluorescent evidence of a humorally mediated microvascular injury syndrome. Significantly elevated factor VIII levels were seen in 17 of 18 patients tested. Antiphospholipids were present in all 18 patients tested, comprising antibodies of phosphatidylethanolamine, beta-2 glycoprotein, phosphatidylcholine, and/or phosphatidylserine. Anti-Ro and/or anti-ribonucleoprotein (RNP) antibodies were seen in 4 patients. Serologic evidence of infection with cytomegalovirus (CMV) was found in 9 patients and parvovirus B19 (B19) in 9 patients; 1 patient was not tested. Molecular studies revealed B19 DNA in 6 of 6 B19-seropositive patients. In situ hybridization studies revealed CMV RNA in pulmonary cells in patients with serologic evidence of active CMV infection despite the absence of cytopathic changes typical of CMV infection. Antiphospholipid antibodies, antiendothelial cell antibodies, and/or endotheliotropic viral infections related to B19 and CMV may be of pathogenetic importance to the evolution of IPF. This report underscores the potential importance of microvascular injury in the evolution of IPF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12710128     DOI: 10.1309/0B06-Y93E-GE6T-Q36Y

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  21 in total

1.  Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercaptoethyl isophthalamide.

Authors:  Rishi B Patel; Sainath R Kotha; Lynn A Sauers; Smitha Malireddy; Travis O Gurney; Niladri N Gupta; Terry S Elton; Ulysses J Magalang; Clay B Marsh; Boyd E Haley; Narasimham L Parinandi
Journal:  Toxicol Mech Methods       Date:  2012-06       Impact factor: 2.987

Review 2.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

3.  Serum analysis of coagulation factors in IPF and NSIP.

Authors:  E Bargagli; C Madioni; N Bianchi; R M Refini; R Cappelli; P Rottoli
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

4.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 5.  Viral infection and aging as cofactors for the development of pulmonary fibrosis.

Authors:  Payal K Naik; Bethany B Moore
Journal:  Expert Rev Respir Med       Date:  2010-12       Impact factor: 3.772

6.  Increased platelet binding to circulating monocytes in idiopathic pulmonary fibrosis.

Authors:  Ahmed Fahim; Michael G Crooks; Alyn H Morice; Simon P Hart
Journal:  Lung       Date:  2014-01-07       Impact factor: 2.584

7.  Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase D and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic acid, in lung microvascular endothelial cells.

Authors:  Rishi B Patel; Sainath R Kotha; Shariq I Sherwani; Sean M Sliman; Travis O Gurney; Brooke Loar; Susan O'Connor Butler; Andrew J Morris; Clay B Marsh; Narasimham L Parinandi
Journal:  Int J Toxicol       Date:  2010-12-03       Impact factor: 2.032

8.  Inhibitor of differentiation 1 promotes endothelial survival in a bleomycin model of lung injury in mice.

Authors:  Huimin Zhang; William E Lawson; Vasiliy V Polosukhin; Ambra Pozzi; Timothy S Blackwell; Ying Litingtung; Chin Chiang
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 9.  Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation.

Authors:  Bethany B Moore; Thomas A Moore
Journal:  Ann Am Thorac Soc       Date:  2015-11

10.  Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis.

Authors:  Masaru Ando; Eishi Miyazaki; Takeo Ito; Shigeo Hiroshige; Shin-ich Nureki; Takuya Ueno; Ryuichi Takenaka; Tetsujiro Fukami; Toshihide Kumamoto
Journal:  Lung       Date:  2010-01-12       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.